Hepatocellular Carcinoma
Conditions
Interventions
Intervention Group:MWA followed by TACE
Control Group:MWA alone
Sponsors
Department of Interventional Oncology,Renji hospital, School of Medicine,Shanghai JiaoTong University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Patients with primary liver cancer aged 18 to 75 years, the expected survival of at least 3 months; (2) Large hepatocellular carcinoma with no more than 3 tumors and a maximum diameter of more than 5 cm and less than 10 cm, pathologically characterized by primary hepatocellular carcinoma (HCC); (3) No portal vein tumor thrombus; (4) Child-Pugh liver function classification A or B; ECOG physical status score of 2; (5) Patients with cirrhosis who show one of the following, such as mild ascites, endoscopic esophageal varices, MELD score of not less than 12; (6) Hematological examination (platelet count> 40×10^9/L, INR <2.0); (7) Renal function (creatinine <2.0 mg/dL); (8) White blood cell count=3.0×10^9/L; (9) Hemoglobin = 8.5g/dl.
Exclusion criteria
Exclusion criteria: (1) Diffuse liver cancer; (2) Cholangiocarcinoma; (3) With portal vein tumor thrombus; (4) Hepatic vein tumor thrombus; (5) lymph node metastasis and extrahepatic metastasis; (6) With clinical hepatic encephalopathy, refractory ascites or uncorrectable coagulation disorders (7) Women in pregancy or lactation; (8) Previously allergic to iodized oil and chemotherapy drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival(OS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Time of Tumor Disease Progression (TTDP);Feasibility of procedure;Feasibility of safety;Local Tumor Progression;Intrahepatic Distant Recurrence;Extrahepatic Metastases; | — |
Countries
China
Contacts
Public ContactZhai B
Department of Interventional Oncology, Renji hospital, School of Medicine,Shanghai JiaoTong University
Outcome results
None listed